A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

NCT06126783 | Completed Phase 3

• 1 other identifier: CIBI311A301
• Study Type: interventional
• Target: 91
• Locations: 1 country
• Sites: 1

Brief Summary

A multicenter, open-label extension study evaluating the efficacy and safety of IBI311 in subjects with thyroid eye disease

Conditions

Thyroid Eye Disease, TED

Outcome Measures

Primary Outcomes (1)

• The response rate of exophthalmos was studied.

  To evaluate the effect of IBI311 on the exophthalmos response rate in the study eye (defined as the percentage of subjects with an exophthalmos reduction of ≥2 mm from baseline in the study eye without an increase of ≥2 mm in the contralaterial eye).

  After receiving IBI311 treatment for 24 weeks

Secondary Outcomes (8)

• Overall responder rate (i.e., percentage of subjects with a ≥ 2-point decrease in Clinical Activity Score [CAS] and a ≥ 2 mm decrease from baseline in proptosis in the study eye, and without corresponding deterioration in the fellow eye in the study eye

  After receiving IBI311 treatment for 24 weeks

• To evaluate the effects of IBI311 on ocular CAS score.

  After receiving IBI311 treatment for 24 weeks

• To evaluate the effects of IBI311 on exophthalmos.

  After receiving IBI311 treatment for 24 weeks

• To evaluate the efficacy of IBI311 in improving contralateral eye.

  After receiving IBI311 treatment for 24 weeks

• To evaluate the efficacy of IBI311 in improving diplopia.

  After receiving IBI311 treatment for 24 weeks

Study Arms (1)

IBI311

EXPERIMENTAL

The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W

Drug: IBI311

Interventions

IBI311 DRUG

The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W

IBI311

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Comply with the test procedure and voluntarily sign the informed consent;
• Male or female subjects aged between 18 and 80 years (inclusive) at the time of FU1 visit;
• For subjects who completed CIBI311A201 double-blind treatment period, the cohort date from the end of CIBI311A201 study was no more than 28 days;
• If the subject is female, it should be postmenopausal or after surgical sterilization or FU1 visit urine pregnancy test negative and agree to take contraceptive measures within 120 days from FU1 visit to the last dose Women of childbearing age; Male subjects should agree to use contraception within 120 days from the FU1 visit to the last dose.

You may not qualify if:

• Visual dysfunction due to optic neuropathy, defined as a decrease of ≥2 lines of best corrected vision within the last 180 days, a new visual field defect, or color difference secondary to optic nerve involvementOften;
• Patients with corneal ulcers that the investigator determined did not resolve after treatment;
• When the FU1 visit predecessor was scheduled to receive orbital radiation therapy or surgery for TED, including orbital decompression, strabismus correction, and eyelid correction, or during the study periodEtc.;
• Poor thyroid function control was defined as free T3 or T4 deviating from the normal reference range of the local research center laboratory by more than 50% during FU1 visit;
• The presence of any other prior disease, metabolic disorder, abnormal results of physical examination or clinical laboratory examination, which may reasonably be suspected to cause contraindications in the use of the test drug, or shadow Diseases or conditions that place subjects at high risk for treatment complications, including, but not limited to, confirmed or clinically suspected inflammatory bowel disease and coagulation Blood dysfunction, history of acute cardiovascular and cerebrovascular disease or treatment within 180 days prior to FU1 visit (including but not limited to: cerebrovascular accident, transient cerebral ischemia, acute myocardial infarction) Death, unstable angina pectoris, coronary artery bypass grafting, percutaneous coronary intervention (except diagnostic angiography), severe arrhythmia, etc.), treatment within the past 5 years or A history of untreated malignancy (squamous cell carcinoma of the skin, basal cell carcinoma, carcinoma in situ of the cervix, prostate in situ, or thyroid that has been successfully resected without evidence of metastasis) Other than papillary carcinoma), serious systemic infection, non-TED caused eye protrusion, etc.;
• At the time of FU1 visit, either ear was present: a history of tinnitus or other hearing impairment; Or abnormal pure tone audiometry (defined as 0.5 1 24 4 kHz mean bone conduction threshold ≥25 dB or either Bone conduction threshold under frequency ≥40 dB);
• When FU1 visited, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) were 3 times higher than ULN;
• When FU1 was visited, Glomerular Filtration Rate (GFR) was \< 30 ml/min/1.73 m2 (MDRD formula: GFR =186× serum creatinine (mg/dl)).-1.154× (age) -0.203× (0.742 \[if female\]), unit conversion of blood creatinine: 1 μmol/L=0.0113 mg/dL);
• The presence of poorly controlled diabetes at FU1 visit (defined as ≥9.0% HBA1C at FU1 visit or a new diabetes medication within 60 days prior to screening\]Dose change of diabetes drugs currently prescribed \> 10%);
• At FU1 visit, poorly controlled hypertension was present, with systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; Or FU1 adjusted blood pressure medication (dose or.) within 30 days prior to visit Type of drug); Renal artery stenosis; Or evidence of unstable blood pressure (including postural hypotension);
• A 12-lead ECG showing a heart rate \< 50 beats/min or \> 100 beats/min at the FU1 visit indicates active heart disease, or an ECG abnormality at the time of the FU1 visit, as the investigator believes Interfering with the interpretation of ECG results during follow-up, especially excluding QTcF \> 500 ms;
• Subjects received systemic or local use of glucocorticoids, immunosuppressants, or biologics (CD20 antibody, interleukin) from the end of CIBI311A201 study until FU1 visit of this study-6 receptor antibody, tetulizumab, etc.) to treat TED;
• Subjects treated TED with selenium or biotin (except multivitamins containing selenium or biotin) from the end of CIBI311A201 study to before FU1 visit of this study;
• Subjects had participated in other interventionary clinical trials (e.g., for drugs, during their 5 half-lives, with older participants) from the end of the CIBI311A201 study until the FU1 visit of this study Allowed; Vitamins and minerals), or attempting to participate in other clinical trials during the study period;
• Pregnant and lactating female subjects;

Sponsors & Collaborators

• Innovent Biologics (Suzhou) Co. Ltd.: lead

Study Sites (1)

Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200000, China

Location

MeSH Terms

Conditions

Graves Ophthalmopathy

Condition Hierarchy (Ancestors)

Eye Diseases, Hereditary; Eye Diseases; Graves Disease; Exophthalmos; Orbital Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Goiter; Thyroid Diseases; Endocrine System Diseases; Hyperthyroidism; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 19, 2023
• First Posted: November 13, 2023
• Study Start: October 20, 2023
• Primary Completion: September 23, 2025
• Study Completion: September 23, 2025
• Last Updated: May 1, 2026

Record last verified: 2026-04

Locations

CN (1)